Understanding the 6.49% Volatility Levels of Maravai LifeSciences Holdings Inc’s (MRVI) Stock in the Past 30 Days

The stock of Maravai LifeSciences Holdings Inc (MRVI) has gone up by 1.29% for the week, with a 13.30% rise in the past month and a 31.28% rise in the past quarter. The volatility ratio for the week is 4.53%, and the volatility levels for the past 30 days are 6.49% for MRVI. The simple moving average for the last 20 days is 8.14% for MRVI stock, with a simple moving average of 2.57% for the last 200 days.

Is It Worth Investing in Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Right Now?

The 36-month beta value for MRVI is also noteworthy at 0.01. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The public float for MRVI is 106.79M, and at present, short sellers hold a 6.88% of that float. The average trading volume of MRVI on April 02, 2024 was 2.70M shares.

MRVI) stock’s latest price update

Maravai LifeSciences Holdings Inc (NASDAQ: MRVI)’s stock price has decreased by -0.01 compared to its previous closing price of 8.60. However, the company has seen a 1.29% increase in its stock price over the last five trading sessions. GlobeNewsWire reported 2024-03-12 that SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of March.

Analysts’ Opinion of MRVI

Many brokerage firms have already submitted their reports for MRVI stocks, with BofA Securities repeating the rating for MRVI by listing it as a “Buy.” The predicted price for MRVI in the upcoming period, according to BofA Securities is $8 based on the research report published on December 12, 2023 of the previous year 2023.

Credit Suisse gave a rating of “Neutral” to MRVI, setting the target price at $14 in the report published on May 23rd of the previous year.

MRVI Trading at 25.35% from the 50-Day Moving Average

After a stumble in the market that brought MRVI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.26% of loss for the given period.

Volatility was left at 6.49%, however, over the last 30 days, the volatility rate increased by 4.53%, as shares surge +13.73% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +38.48% upper at present.

During the last 5 trading sessions, MRVI rose by +1.94%, which changed the moving average for the period of 200-days by -37.96% in comparison to the 20-day moving average, which settled at $8.00. In addition, Maravai LifeSciences Holdings Inc saw 31.28% in overturn over a single year, with a tendency to cut further gains.

Stock Fundamentals for MRVI

Current profitability levels for the company are sitting at:

  • -0.1 for the present operating margin
  • 0.48 for the gross margin

The net margin for Maravai LifeSciences Holdings Inc stands at -0.42. The total capital return value is set at -0.02. Equity return is now at value -24.75, with -6.31 for asset returns.

Based on Maravai LifeSciences Holdings Inc (MRVI), the company’s capital structure generated 0.56 points at debt to capital in total, while cash flow to debt ratio is standing at 0.24. The debt to equity ratio resting at 1.28. The interest coverage ratio of the stock is -0.63.

Currently, EBITDA for the company is 44.58 million with net debt to EBITDA at 4.71. When we switch over and look at the enterprise to sales, we see a ratio of 4.06. The receivables turnover for the company is 5.19for trailing twelve months and the total asset turnover is 0.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.00.

Conclusion

In summary, Maravai LifeSciences Holdings Inc (MRVI) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts